Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $13.41 and traded as high as $18.99. Assembly Biosciences shares last traded at $18.56, with a volume of 27,519 shares changing hands.
Analysts Set New Price Targets
A number of research firms have issued reports on ASMB. HC Wainwright reaffirmed a "neutral" rating on shares of Assembly Biosciences in a report on Monday, March 24th. Wall Street Zen lowered Assembly Biosciences from a "buy" rating to a "hold" rating in a report on Monday, March 24th. Finally, Guggenheim began coverage on Assembly Biosciences in a report on Tuesday, March 25th. They issued a "buy" rating and a $31.00 target price on the stock.
Check Out Our Latest Analysis on ASMB
Assembly Biosciences Price Performance
The firm has a market cap of $143.21 million, a price-to-earnings ratio of -3.01 and a beta of 0.62. The firm has a 50 day moving average price of $15.56 and a 200-day moving average price of $13.50.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($2.01) by $0.84. Assembly Biosciences had a negative return on equity of 131.77% and a negative net margin of 124.15%. The firm had revenue of $9.42 million for the quarter, compared to analyst estimates of $7.41 million. On average, sell-side analysts expect that Assembly Biosciences, Inc. will post -6.87 EPS for the current fiscal year.
Hedge Funds Weigh In On Assembly Biosciences
Several hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in Assembly Biosciences by 225.6% during the 4th quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company's stock worth $180,000 after purchasing an additional 7,918 shares during the last quarter. American Century Companies Inc. acquired a new stake in shares of Assembly Biosciences in the first quarter valued at about $113,000. Marshall Wace LLP boosted its position in shares of Assembly Biosciences by 16.5% during the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock valued at $234,000 after purchasing an additional 2,098 shares in the last quarter. Palumbo Wealth Management LLC boosted its holdings in Assembly Biosciences by 57.4% in the first quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company's stock worth $172,000 after acquiring an additional 6,559 shares in the last quarter. Finally, Man Group plc bought a new position in Assembly Biosciences in the fourth quarter worth approximately $309,000. Institutional investors and hedge funds own 19.92% of the company's stock.
Assembly Biosciences Company Profile
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Featured Articles
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.